Vaxart (VXRT) 4 May 232023 Q1 Earnings call transcript

Greetings and welcome to Vaxart Business Update and First Quarter 2023 Financial Results Conference Call. A question-and-answer session will follow management's opening remarks. Individual investors may submit written questions to ir@vaxart.com.

As a reminder, this conference is being recorded.

I would now like to turn the webcast over to your host, Ed Berg, Senior Vice President and General Counsel.

to welcome and afternoon, today's call. Good

Chief from Dr. Sean us James Chief Phillip Vaxart Scientific are Officer; Executive Cummings, Lee, and Officer; Chief Floroiu, Medical Officer. Tucker, Dr. Andrei Officer; Joining Financial Founder Chief and

including operations to and financial Before during about everyone trials. business guidance, statements make statements, its this would the regulatory about and may that including Vaxart future remind statements or we and call, company's ongoing I development planned get forward-looking started, progress, its like product conference financial its strategies results, clinical

Annual these differ statements important Actual from in filed Report regulatory with call. any in of results could materially recently most on reports XX-K uncertainty forward-looking date Risk other including to other obligation those the Vaxart's of of discussed number and in SEC. statements section development the to and filed this undertakes and described process, periodic forward-looking a Vaxart no clinical update the Form inherent after due risks factors, the Factors

now Andrei? to Andrei turn Floroiu. over the I'll call

Ed, and thank On norovirus you today. pill our us team made during you, call program quarter. have all the to vaccine our we joining highlight today’s for will oral of on the you progress Thank

plans will unique data pan-betacoronavirus that We benefits for demonstrates of on discuss also vaccine updates our the oral an and showcase our platform.

study year. remain and GXX candidate both vaccine We Phase our results dose ranging milestones data this dose monovalent our X candidate. Phase study the vaccine planned XXXX track norovirus, with our CHALLENGE initiated later on with bivalent the notably anticipated ranging norovirus most norovirus our we Starting study X ongoing for to for our oral of quarter, in for for deliver on

why program details will and these moment, studies global and on on studies this why but first, James public a so health are a for quick reminder important more in provide both economic health a which we're pill is leads a committed public Norovirus significant norovirus approved burden countries vaccine. is and oral approach. there in significant issue, no to Vaxart developed to vaccine

infected each burden under of important predominantly are more There the US XX in XX million annual is than alone. and adults. that million of More segments, and norovirus older children the in are note It resulting five million in an to the age affects year age people US billion about US XX. than in $XX XX older of the over the two kids about age adults disease

there to total who childcare as Additionally, vaccine approximately approximately from opportunity such can and are a million domestic Americans healthcare market Americans. XX our other bringing providers, XX norovirus million benefit service

people norovirus look In know it where is people are the gather or at that and norovirus, is equal, the number US, workplaces, most been but current many large other concerned is of total the in events, cases, illness foodborne by you frequent for everyone in about risk of most number. schools, salmonella you far full at if places

the the able vaccine symptoms experience who tremendous People the our around potential both and disease the address program missing the not We norovirus US to functions. has that that and believe work carries perform are to their and and world. norovirus need burden norovirus school in daily are

similar responses Today, natural infection trials a nearly young and with to data norovirus. the comparable we in result vaccine injectable clinical adult enrolled XXX data long-lasting elderly norovirus is from from seen strong, subjects. shown have completing population both be have vaccines. that generally have produced These to that immune from not six And our

community financial event available on informative this educate is section a replay the the and of and hope the vaccine. virtual global event of program These the at opportunity that KOL about norovirus In for safe, we our www.vaxart.com. many We our need you norovirus the perspectives were shared readily join Relations on with A norovirus effective needs in to a showcased of our a call able differentiated leaders for we sponsored experts that development. insights vaccine. magnitude the that norovirus we Investor as and March, unmet to on vaccine their deployable continue website on

milestones Looking and ahead, we we have achieve track several to important on this clinical year them. remain

mid-XXXX. we the report to bivalent expect top-line vaccine First, Phase X ranging candidate, our on norovirus study data dose ongoing of in

year. Next, vaccine CHALLENGE X ongoing this those breast GXX Foundation trial in candidate we candidate norovirus funded anticipate young in clinical Phase vaccine of of reporting to and we top-line evaluate the norovirus forward monovalent quarter to look of year, the initiating use Gates data to Melinda this transfer our antibodies from And Bill study milk then, or antibodies third and to the ability infants. the

we potential the program to of advance have this are vaccine vaccine milestones of these continue globally platform. our together, while Vaxart’s support providing to advancement and and further of the potentially opportunity trial, for by relevant, both validation promise technology. also continued the nationally remain Taken encouraged oral Norovirus safety our pill pill the norovirus to norovirus

I'll Now, James James? over a norovirus of our call program. for the turn to review

our and with We're Vaxart platform. the really meaningful efforts for to make proud of their advance progress clinical continued Thanks, team Andre. our mission

which our first the the past quarter norovirus candidate. Recall disease GXX, genotypes, important candidate X bivalent majority this have contains norovirus humans ranging Phase the During first very dose of caused this in study of subject dosed that oral we year, the and XX years. in the GXX two of vaccine over

trial here enrolled As in at United adults the healthy this three States. XXX sites reminder, a

arms and of development. Phase and immunogenicity the subjects endpoints order in The placebo. Sentinel remaining safety are a subjects the vaccine has vaccine level primary XX first dose the determine vaccine The were to and or arm XX high subjects. the subjects placebo open-label, high-dose XX to or randomized dose has for received Each low X

end the XXXX. to this phase will in completed an study in the of If to of Xb Enrollment top-line meeting middle report Phase study was leading expect with be mid-April successful, from next in we data the and year. X the step a FDA

immune This cohorts to the GXX announced X protection also of to and vaccine monovalent study is gastroenteritis. of expansion a efficacy number in risk to completed vaccine correlative In identify in in and ongoing a to continue our Phase acute top-line ongoing. Enrollment study data XXXX. of norovirus the and between this CHALLENGE our designed March, we candidate. report safety reduction responses norovirus the is quarter measuring the expect a and/or infection double-blinded the study third norovirus in in we of

noravirus systemic for lasted boosted were In Vaccine to norovirus above XX% April, this Washington. both XX be similar years presented very response induces than the data to D.C. at were on the rates XX days; in year; that responses bivalent XXX after one following: responses World immune vaccine aged those more disclosed many were study in candidate responses; elderly, can the those and has our in immune demonstrate XX Congress the has all well to finally, data trials I from pill And high vaccine broad responses, been including advantages of and XX. norovirus this aged our it clean tolerated via Vaxart’s program clinical our and safety vaccine immune they for younger responses adults, oral in to-date. broad profile dose; in has These immune mucosal previously durable; a

at in block milk transmission. antibodies Sean on ability Netherlands. presentations three CSO Rotterdam, make be the to Founder and Xth presenting a our Dr. and potential Virus Tucker, breast, the The will will we week, International Next Calici Conference paper

in to-date, Dr. boost efforts XX Vaxart’s of effective candidate immunization elderly of potent vaccine oral an I'll Becca months, subjects. as overview present as studies our additional And lastly, immune bivalent demonstrating details administration in vaccine that after bivalent data providing our Flitter is norovirus will inducing presenting responses. at be well on

We you as candidate submission possible our provide on target potential our progress forward believe the we Phase clinical as updates continue FDA of from updating our bivalent We and in approval. look concurrent X to to trials. a norovirus we BLA

Tucker and I'll now over Sean? pan-beta our for program. Founder to Officer, turn Science an on Coronavirus call Chief our Sean update the Dr.

Thanks, James.

and the the objectives: easy research it Covid-XX studies vaccine Our and leaders induces of it transmission; to previously is response; Vaxart that vaccine from scientific of transmission I responses; T-cell a potent it creates room governmental to vaccines. clinical it tremendous in immune ability responses our boosts temperature other Vaxart immune all virus publishing it responses; serum Covid-XX it in SARS-CoV-X existing vaccine. is month. We and and last beta World stable; induces following front data Vaccine it important of data mucosal reactivity published important made is in boost importantly has and antibody administer; the achieving variants preclinical and coronaviruses; during believe has a serum Covid most demonstrating gatherings and it block presenting presented profile team data favorable Congress neutralizing inhibit cross platform’s can antibody strides

oral able in to-date reported we Based of vaccine pan-beta on we we be clinical have mucosal create studies, coronavirus may believe data cross-reactivity vaccine. Covid all our to

new continue the threats tremendous $X and Covid-XX coronaviruses future-proof tool to either gauge clinic other by when look next-generation evidenced the reported and vaccine. There's vaccine proposed to to plan our We Biden goal current viruses emerging to to to in obtaining would We billion interest Such we protect for preparedness. regulatory the of such make continuing up circulating constructs or vaccines a pandemic continued and ready. makes the develop for these next-generation of we vaccine valuable cross-reactivity approach program. sense. with pan-beta government, enhanced easy to coronavirus making it that as this advance governmental both commitment believe to pan-beta against against bodies are We for coronovirus the with Administration’s it Coronavirus beta a from funding coronavirus forward

over deep the financials. a call Phil I'll of turn Phil? now the to for discussion

compared for first The XXXX months are press norovirus cash restricted of primarily results three in we XXst cash as securities was cash summarized decrease million Vaxart to due operations financial XXXX as and details release. equivalents, of cash, ended million, today's to in program. XXXX. Sean. advanced our of the our of first marketable Thanks, with $XX.X of The quarter $XX.X December the used

blood setbacks quarter the you of for position behalf continue provides thank to our second are, like the I'd current of We time XXXX. On expect to way into us today. your with cash all

the call open now for will questions. your We

And to like from open. it Mayank come looks Riley. line going is question is first your B. Mayank, your Mamtani

for Thanks questions. Good our afternoon taking team.

opportunity miles talking here mRNA advantages burden seem a this a you obviously have market you differences, being join relative are that vaccine, little And the about peer terms X. norovirus validates a And have while, you just Phase which have a the talk disease and say, platform I in follow-up. for guys of to you been mRNA? bit Could relative then in your with platform a develop ahead in to So, to effort,

surfaces mucosal Hi an a the intestinal is will in good advantage. we standpoint antibodies I think our fact, We and Maya. strong obviously, intestinal listening something that norovirus little space. Yeah, bit certainly know about, let we you the in very very we me from think antibody have of platform tell do be responses make

As good you responses, tend a mRNA be to making very at serum vaccine but little know, those can more transient. be antibody

have I least at last this is that think data XXX our norovirus least more at antibodies we than days. in our can in for serum

think, further I obviously, ahead. I significant we we're And think So, have some advantages.

our are on had to And of And where guys Great. designed study study study events great. if as the plan? of comment original of you been of when monovalent, able thanks versus that that you the guys to for you sort And learned relative then anything CHALLENGE how have would on this executing you the the expectation That sort on you taking else be for the sort are? questions. you the have

don't Sean? one This James. I this take Why is

that sample your The of more studies occurrence CHALLENGE see typically is what analysis. in you world built than size for So in they're nature descriptive real for statistical study this disease. the aggressive recall primarily

the looking As we're understand really operates. to vaccine how

including, To number effect viral a severity disease infectivity but acute were AGE, have shedding, of a severity. or measures limited to do gastroenteritis, of a decrease and in on at this, looking in we decrease on not effect

taking Got questions. the it. for Thanks

from next with is Our Roger Jefferies. Roger, to your come question is open. Instructions] [Operator going Song line

A question. few for Thanks ones from the us. update quick and our Great. taking

make one first that. will so that in to design Thank know year, the the can just you the the the forward? will have based a is potential go/no-go you a immunogenicity for the that us after Phase So data decision potentially going what And I will the the expectation and what you understanding for how bivalent on be data mid data the immunogenicity let X for do study in year? Phase see Xb, you. follow-up you're

Roger. This is James.

So, a take at I'll stab that.

our immunogenicity as look and the the X, knock strengths at past compare and in which our on portfolio For we're the has bivalent take is different Phase study, wood a groups. we'll those of XXX doses safety to immunogenicity looking also construct. But our just the of looking to-date we'll safety, both norovirus well-tolerated. look two at And two

think Phase post Xb, the a And follow-on will we data Phase at I with get of sort the would the what have larger those months. we - that study safety things dose to look study, FDA. to can discussion then a two to discussion enough take the to to so take X are judge likely follow-on a the that few

successful So, would all potentially we project if XXXX.

CHALLENGE you Xb you data you pivotal? the will monovalent data for or would similar the Phase the do as and from study the moving manage Phase in also X have before Got you the do will bivalent, bivalent bring initial study the you. And XQ Xb will CHALLENGE with the the so to larger as data CHALLENGE then given to with Phase something do the expect the pivotal moving monovalent you

Well, are such we just A I study of data from study the sequence mid-year. Part comparison think that Phase will the X, events to the XXX have top-line

study we conversation, the this have top-line for of CHALLENGE this in year. the QX will in said we As data

those next data out are points we important our two fairly as So, map steps.

Does that if quite got that? I Roger, because I'm answer question, not your sure

Yeah.

but can for do you move before another Just, question CHALLENGE later-stage you I development? also study curious, just your into think, the need bivalent

that's the in a have I of not whether the discussion is will to studies, with talking not we that's about. be to this a or have or agency Well, data that agencies requirement regulatory after additional think something we terms

Thank it. Got you.

of concludes Okay. the portion audio the That Q&A.

So Berg turn over to for Q&A. I'll it now Ed the written

any? online James, you. of Thank question those you. was with you this And quarter? of context FDA discussions is additional what have number first for the so, We've a if if questions. the this had discussions Did

a had with the with the I as had a once But in haven't we Thanks study completed for past mentioned for quarter. FDA need larger post-Phase is formal new planned not meeting Ed. this Phase a to past discussions for We really and X the quarter plan do FDA Xb Roger. discussions the

candidate Phase X? Also, success How you to is correlates important probability norovirus of norovirus, protection this Sean. about the you. identifying subject of the a what question overall for is program? on question the too, tell could follow-up Thank And those correlative vaccine and identifying in

up are Yeah, what thanks, make Ed. it Yeah, important it’s you if and clinical impact efficacy. possibly helps reflective you trials schedule certainly there's understand help understanding late-stage what the of development can – to in change success immune speeding for you vaccination any parameters dose know look for in and

your have, path this trials, your nice but Phase your is because course, Of it reduce X a to certainly up study. the have, beat it's to definitely of and and not size - can’t

Sean. Thanks,

time? be We have This would herd have vaccinate protected for one the you more for norovirus over if program. infants, immunity question adults James. Would norovirus a on one is role

norovirus approved interesting Yeah, as by no affected spread the there. that's vaccine be vaccine you question. infectivity currently there's know, an It's, would because, unknown and out how

in us the are or health well-known if you However, several of inform of study for Japan – showed also rate were for mortality of significantly. all that elderly vaccinate you the improve there studies young influenza, that caused There's show decreased relatively that causes when a all deaths children, vaccinated population children young the adults. that out

we protect know health Now that acquire not against their global that's be and then all portion transmit we address. of you disease children And a to families. might hope able Illness, to to that but

you. Thank

have. might program to next-gen next-generation $X in Biden Sean want is, and call? on on reported at Administration’s Washington And thinking in RFI pan-beta We program question The The Post the proposal billion the answer is potential the you that you're for that I the the funding. actually Coronavirus is and that Administration about referenced you The Does vaccines coronavirus. the referenced question. report change all, have Andre, a Biden this. the how coronavirus we vaccine think next Covid question

think report it's reflected I scientific a Andrei? announcement to current of the approach. for of vaccines is made. consensus Again, Yeah, vaccine can be But it a improvements changes the with definite. don't question. good is community the the next-generation the positive probably funding that potential our

mucosal asked, the that, the what on yeah, is requirements was focus very the said people see the of and we can Administration our from immunity well see these Sean Biden I as approach what read confirmation Yeah, and like still We as is have progress RF I our test. and platform. that kind

it. to initiative in quite forward So looking this we're we we are by participate how encouraged seeing can and

one Covid. clinic? This timeline coronavirus advancing on Thank for candidate you. a have at you One vaccine final question. a for Again is Andrei. Sean. Do pan-beta the

mean, research increased coronavirus believe at not having are multiple to I a pan-beta Yes, which in this factors. potent in constructs continuing guidance newer Again, We're we to certainly make on timing potential we depends develop any candidates vaccine. time. providing

Okay. back That's the the questions over operator. to have. turn I'll it all we

your you. call. Thank This concludes Okay.

You you may thank disconnect for now and again joining.